Compare Macy's Inc (M) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs GeneDx Holdings Corp — how do they compare? Macy's Inc trades at $23.84 (market cap $6.45B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Macy's Inc is far larger — about 2.6× GeneDx Holdings Corp's market cap, and Macy's Inc pays a 3.12% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| M | WGS | |
|---|---|---|
Market Cap | $6.45B | $2.44B |
Sector | Consumer Cyclical | Technology |
52-Week High | $26.21 | $167.51 |
52-Week Low | $12.73 | $34.51 |
Enterprise Value | $10.26B | $2.48B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $23.92, down 3.94% in the last session, with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics including a P/E of 10.13 and P/S of 0.3, while maintaining positive cash flow generation. Recent institutional buying and analyst coverage indicate growing confidence in the company's turnaround strategy.
The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 4% upside potential. Key risks include retail sector headwinds and competitive pressures, but strong institutional interest and improving fundamentals support the case for gradual recovery. The dividend payment scheduled for July provides additional shareholder return.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
